News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment interruptions news

Show

From To
Treatment interruptions
CROI: Risk of treatment interruption persists after restarting HAART

The detrimental effects of interrupting antiretroviral therapy are reduced, but not entirely reversed, after restarting treatment, researchers with the SMART study reported on Monday at

Published
05 February 2008
By
Liz Highleyman
Side-effects
High prevalence of asymptomatic heart disease in HIV-positive patients

Asymptomatic ischaemic heart disease is common in HIV-positive individuals, according to a subanalysis of the SMART treatment interruption study published in the January 11th edition

Published
09 January 2008
By
Michael Carter
Adherence
Up to 40% of ART recipients in Africa have died or discontinued treatment within two years

Up to 40% of all patients receiving anti-HIV drugs in sub-Saharan Africa are thought to have either died or discontinued treatment within two years, according

Published
17 October 2007
By
Edwin J. Bernard
Resistance
ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance

Stopping NNRTI treatment seven to ten days before stopping the nucleoside analogue backbone does minimise the risk of developing NNRTI resistance, a Thai study has

Published
19 September 2007
By
Derek Thaczuk
Treatment interruptions
IAS: ART interruption particularly unsafe for HIV-positive patients coinfected with hepatitis B or C

Intermittent interruption of antiretroviral therapy appeared particularly unsafe for HIV-positive people coinfected with hepatitis B or C in the SMART study, researchers reported on Tuesday

Published
24 July 2007
By
Liz Highleyman
HIV treatment
Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated

The license for nelfinavir (Viracept) has been temporarily suspended by European drug regulatory authorities. The move comes two weeks after it was discovered that

Published
21 June 2007
By
Michael Carter
HIV treatment
Near-global nelfinavir (Viracept) recall 'very difficult situation'

On June 14th, WHO issued a statement on the recall, saying that "Roche informed WHO on 8 June 2007 of its global recall of its

Published
20 June 2007
By
Edwin J. Bernard
Transmission and prevention
CROI: SMART substudy finds people on treatment less likely to transmit HIV, and may take fewer risks

A substudy of sexually transmitted infections and sexual risk-taking among participants in the large SMART study of structured treatment interruptions has found that people on

Published
04 March 2007
By
Gus Cairns
Side-effects
CROI: SMART analysis reveals slightly elevated risk of cardiovascular disease in people who interrupt therapy

The latest analysis of data from the SMART study suggest that HIV-positive people who periodically interrupt therapy based on CD4 cell counts have a slightly

Published
27 February 2007
By
Liz Highleyman
Treatment interruptions
Studies finds risks in guided treatment interruptions even at higher CD4 cell threshold

A study published in the January 11th edition of AIDS found that “guided treatment interruptions” in people with CD4 cell counts greater than 350 cells/mm3

Published
01 February 2007
By
Derek Thaczuk
← Prev1...45678...10Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.